TMR

Earnings Growth of Hospital Acquired Pneumonia Drugs Market may go to US$3.8 bn; Need for Advanced Drugs, Phase III Drugs Rising Its Demand

Press Release   •   Jan 17, 2017 08:46 EST

Hospital-acquired pneumonia also called as healthcare associated pneumonia or nosocomial pneumonia is acquired in hospital premises. Unlike community acquired pneumonia hospital acquired pneumonia is mainly caused due to multidrug resistant microorganisms. The report analyzes the market for late stage candidates for treatment of nosocomial pneumonia, and also provides a detailed review of drugs in early stages of clinical trials. The report studies and estimates market for six late stage along with an elucidation of ten early stage candidates for nosocomial pneumonia treatment.

View Exclusive Global Strategic Business Report of Hospital Acquired Pneumonia Drugs Market at: http://bit.ly/2js3EV7

Unlike generally acquired infections and pneumonia, hospital acquired infections are highly resistant to conventional drugs. This creates major problems for patients who are already under treatment for other ailments. Hospital acquired pneumonia usually shows immunity to multiple drugs. It usually becomes a case of comorbidity, drastically reducing a weaker patient’s chances of recovering.

According to the report, there are six drugs currently in the final phases (phase III) of the global hospital acquired pneumonia market pipeline. Of these, five are investigational drugs while another is a vaccine. These are considered to be the leading answers to curbing the high prevalence of hospital acquired pneumonia. Moreover, there are ten other drugs in the early stages of the global hospital acquired pneumonia market pipeline.

As stated in the report, the six phase III drugs in the global hospital acquired pneumonia market pipeline are Tedizolid phosphate by Cubist Pharmaceuticals, Amikacin inhale by Bayer Healthcare, Ceftolozane/tazobactam, Synflorix by GSK, Plazomicin by Achaogen, Inc., and Ceftazidime/avibactam by AstraZeneca PLC.

With a maintenance of schedules, these six drugs are expected to be available in 2017, if they are approved.

One of the major trends visible in the global hospital acquired pneumonia market is the shift in preference from conventional antibiotic drugs to the modern, novel biological drugs. This can be noticed in the fact that most of the final stage drugs in the global hospital acquired pneumonia market pipeline are biological drugs.

The report also takes up citations from the U.S. CDC, according to which at least 63% of the variants of acinetobacter are resistant to multiple drugs. Meanwhile, the most prominent MRSA was the most dangerous and prominent organism associated with hospital acquired pneumonia. The CDC had also revealed that nearly 11,000 of the 80,400 patients who contracted MRSA-based HAIs had died.

The WHO adds to this with a study that revealed low income and medium income families to be the most susceptible to HAIs. These factors need to be considered by the global hospital acquired pneumonia market in the development of new drugs.

Read the Current Market Analysis of Hospital Acquired Pneumonia Drugs at: http://www.transparencymarketresearch.com/hospital-acquired-pneumonia-drugs.html

The key players in the global hospital acquired pneumonia market pipeline for now, include the companies named above. For the overall global hospital acquired pneumonia market, the report takes into consideration the player profiles of Basilea Pharmaceutica Ltd., Meiji Seika Pharma Co. Ltd., Cubist Pharmaceutical, Valneva SE., Aridis Pharmaceutical, Bayer Healthcare, GlaxoSmithKline, Merck & Co., Achaogen, Inc., and AstraZeneca PLC.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.